J&J says its lung cancer drug combination keeps people alive longer 0 07.01.2025 18:59 CNBC Johnson & Johnson said its lung cancer regimen – Rybrevant plus Lazcluze – keeps people alive for at least a year longer than AstraZeneca's Tagrisso. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа
